198 related articles for article (PubMed ID: 37575220)
1. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
Eckhoff AM; Brown MC; Landa K; Naqvi I; Holl EK; Boczkowski D; Fletcher A; Rhodin KE; Giang MH; Sullenger B; Beasley GM; Allen PJ; Nair SK
Front Immunol; 2023; 14():1116034. PubMed ID: 37575220
[TBL] [Abstract][Full Text] [Related]
2. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical FAP Expression Reflects
Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
[TBL] [Abstract][Full Text] [Related]
5. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
6. Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms.
Yamaguchi A; Tazuma S; Tamaru Y; Kusunoki R; Kuwai T; Kouno H; Toyota N; Sudo T; Kuraoka K; Kohno H
BMC Gastroenterol; 2022 Dec; 22(1):529. PubMed ID: 36539713
[TBL] [Abstract][Full Text] [Related]
7. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
Hernandez S; Parra ER; Uraoka N; Tang X; Shen Y; Qiao W; Jiang M; Zhang S; Mino B; Lu W; Pandurengan R; Haymaker C; Affolter K; Scaife CL; Yip-Schneider M; Schmidt CM; Firpo MA; Mulvihill SJ; Koay EJ; Wang H; Wistuba II; Maitra A; Solis LM; Sen S
Clin Cancer Res; 2022 May; 28(9):1938-1947. PubMed ID: 35491652
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas.
Mo S; Zou L; Hu Y; Chang X; Chen J
Mod Pathol; 2023 Sep; 36(9):100223. PubMed ID: 37244388
[TBL] [Abstract][Full Text] [Related]
10. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
[TBL] [Abstract][Full Text] [Related]
11. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
[TBL] [Abstract][Full Text] [Related]
12. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
[TBL] [Abstract][Full Text] [Related]
15. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
[TBL] [Abstract][Full Text] [Related]
16. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
[TBL] [Abstract][Full Text] [Related]
19. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
